Molchanov O.L. Molchanov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Molchanov O.L. Molchanov has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Vitaliy Fyodorovich Bezhenar
Federal State Budgetary Educational Institution of Higher Education “First St. Petersburg State Medical University named after Academician I.P. Pavlova» of the Ministry of Health of Russia
2 shared publications - A. Yu. Ralnikova
Pavlov University
1 shared publication Arakelyan B.V. Arakelyan
1 shared publicationDmitrii V Baibuz
Saint Petersburg State University
1 shared publication- Evgeniа B. Troik
Academician I.P. Pavlov First St. Petersburg State Medical University
1 shared publication - Gabelova K.A. Gabelova1 shared publication
Latest Publications
- 31 July 2023
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 7_2023, 109-118
The role of sensitization to progesterone in improving the treatment of endometriosis-associated pelvic pain
- 31 July 2023
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 7_2023, 109-118
The role of sensitization to progesterone in improving the treatment of endometriosis-associated pelvic pain
- 3 March 2020
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 2_2020
Successful organ-sparing surgical treatment in a patient with the placenta previa growing into the uterine scar region
- 3 March 2020
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 2_2020
Successful organ-sparing surgical treatment in a patient with the placenta previa growing into the uterine scar region
- Open Access
- 15 October 2019
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 21 (5) , 20-24
The role of vitamin D deficiency in the risk for uterine fibroids relapse after laparoscopic conservative myomectomy in women of reproductive age
Relevance. Due to the high prevalence of uterine fibroids in women of reproductive age and the negative impact on reproductive health, one of the priority tasks of specialists is to search not only for new therapeutic methods, but also for ways to prevent this disease. Aim. To determine the role of vitamin D deficiency in the risk of uterine fibroids recurrence after surgical treatment in women of reproductive age. Materials and methods. A comparative analysis of the recurrence rate of uterine fibroids in patients of reproductive age after surgical treatment. The study involved 49 women of reproductive age 20-39 years (average age 31.5±4.3 years) with unrealized reproductive plans. All underwent surgical treatment in the scope of laparoscopic conservative myomectomy for uterine fibroids with different symptoms. All patients were given vitamin D levels. Results. In 93.5% of cases, the risk of recurrence of uterine fibroids increases at vitamin D levels below 34.5 ng/ml, when reaching 38.6 ng/ml and above, the risk of reformation of nodes is minimal. Conclusions. When the vitamin D level exceeds 38.6 ng/ml, it is possible to minimize the risk of recurrence of uterine fibroids in women of reproductive age, thereby avoiding repeated surgical interventions and associated complications.
- 15 October 2019
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 21 (5) , 20-24
Open AccessThe role of vitamin D deficiency in the risk for uterine fibroids relapse after laparoscopic conservative myomectomy in women of reproductive age
Relevance. Due to the high prevalence of uterine fibroids in women of reproductive age and the negative impact on reproductive health, one of the priority tasks of specialists is to search not only for new therapeutic methods, but also for ways to prevent this disease. Aim. To determine the role of vitamin D deficiency in the risk of uterine fibroids recurrence after surgical treatment in women of reproductive age. Materials and methods. A comparative analysis of the recurrence rate of uterine fibroids in patients of reproductive age after surgical treatment. The study involved 49 women of reproductive age 20-39 years (average age 31.5±4.3 years) with unrealized reproductive plans. All underwent surgical treatment in the scope of laparoscopic conservative myomectomy for uterine fibroids with different symptoms. All patients were given vitamin D levels. Results. In 93.5% of cases, the risk of recurrence of uterine fibroids increases at vitamin D levels below 34.5 ng/ml, when reaching 38.6 ng/ml and above, the risk of reformation of nodes is minimal. Conclusions. When the vitamin D level exceeds 38.6 ng/ml, it is possible to minimize the risk of recurrence of uterine fibroids in women of reproductive age, thereby avoiding repeated surgical interventions and associated complications.
- Open Access
- 29 May 2019
- Published by ECO-Vector LLC in Journal of obstetrics and women's diseases
- Vol. 68 (2) , 51-58
Possibilities of applying antigestagens in therapy
In the modern medical practice, anti-progestogen therapy is widely used where RU-486 (mifepristone) is one of its variants. However, the potential of this therapy in the treatment of various pathologies is far from exhausted. In the general medical practice, it is possible to use mifepristone (RU486 metabolite) to control hyperglycemia in patients with Cushing’s syndrome, in the treatment of endogenous hypercorticism syndrome and metastatic cancer (melanoma, breast cancer, meningioma and other localizations). In the gynecological practice, it is used for contraception and early termination of pregnancy. Of particular interest is the use of antigestagens in the therapy of uterine leiomyoma. In recent years, the conservative treatment of uterine leiomyoma, aimed at the restoration and preservation of women’s reproductive health, has become a priority task for specialists. Therapy with antigestagens, in particular mifepristone, is seen as a possible worthy alternative to invasive methods of treating uterine fibroids, in which there are still many “white spots” that need to be studied.
- 29 May 2019
- Published by ECO-Vector LLC in Journal of obstetrics and women's diseases
- Vol. 68 (2) , 51-58
Open AccessPossibilities of applying antigestagens in therapy
In the modern medical practice, anti-progestogen therapy is widely used where RU-486 (mifepristone) is one of its variants. However, the potential of this therapy in the treatment of various pathologies is far from exhausted. In the general medical practice, it is possible to use mifepristone (RU486 metabolite) to control hyperglycemia in patients with Cushing’s syndrome, in the treatment of endogenous hypercorticism syndrome and metastatic cancer (melanoma, breast cancer, meningioma and other localizations). In the gynecological practice, it is used for contraception and early termination of pregnancy. Of particular interest is the use of antigestagens in the therapy of uterine leiomyoma. In recent years, the conservative treatment of uterine leiomyoma, aimed at the restoration and preservation of women’s reproductive health, has become a priority task for specialists. Therapy with antigestagens, in particular mifepristone, is seen as a possible worthy alternative to invasive methods of treating uterine fibroids, in which there are still many “white spots” that need to be studied.